Unusually prolonged rebound cataplexy after withdrawal of fluoxetine

Neurology

Volumn 65, Issue 6, 2005, Pages 967-968

  Poryazova, Rositsa ^a   Siccoli, Massimiliano ^a   Werth, Esther ^a   Bassetti, Claudio L ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE;

ADULT; ARTICLE; CASE REPORT; CATAPLEXY; DISEASE SEVERITY; DRUG WITHDRAWAL; ELECTROMYOGRAPHY; ELECTROOCULOGRAPHY; FEMALE; HUMAN; MUSCLE ATONIA; MUSCLE TONE; MUSCLE TWITCH; NARCOLEPSY; POLYSOMNOGRAPHY; PRIORITY JOURNAL; REBOUND; REM SLEEP;

EID: 25444447775     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000175978.61048.62     Document Type: Article

References (7)

1. Sturzenegger C, Bassetti CL. The clinical spectrum of narcolepsy with cataplexy: a reappraisal. J Sleep Res 2004;13:395-406.
2. Aldrich MS, Rogers AE. Exacerbation of human cataplexy by prazosin. Sleep 1989;12:254-256.
3. Littner M, Johnson SF, McCall WV, et al. Practice parameters for the treatment of narcolepsy: an update for 2000. Sleep 2001;24:451-466.
4. Langdon N, Shindler J, Parkes JD, Bandak S. Fluoxetine in the treatment of cataplexy. Sleep 1986;9:371-373.
5. Guilleminault C, Raynal D, Takahashi S, Carskadon M, Dement W. Evaluation of short-term and long-term treatment of the narcolepsy syndrome with clomipramine hydrochloride. Acta Neurol Scand 1976;54:71-87.
6. Martinez-Rodriguez J, Iranzo A, Santamaria J, et al. Status cataplecticus induced by abrupt withdrawal of clomipramine. Neurologia 2002;17:113-116.
7. Feige B, Voderholzer U, Riemann D, Dittmann R, Hohagen F, Berger M. Fluoxetine and sleep EEG: effects of a single dose, subchronic treatment, and discontinuation in healthy subjects. Neuropsychopharmacology 2002;26:246-258.